Inventor · disambiguated record
Terrence Howell
Also filed as: HOWELL TERRENCE · HOWELL TERRENCE M
22 granted patents·10 pending applications·321 citations·filing 2001–2012
96Inventor score
Files withMETAPROTEOMICS LLC16TRIPP MATTHEW L5ASHNI NATURACEUTICALS INC4BABISH JOHN G1METAPROTEONICS LLC1
Top patents by PatentIndex Score
32 records- 0197US7431948B2Compositions that treat or inhibit pathological conditions associated with inflammatory responseMETAPROTEOMICS LLC·Filed 2006·Granted Oct 7, 2008·46 cites·23 claims
- 0296US7195785B2Complex mixtures exhibiting selective inhibition of cyclooxygenase-2METAPROTEOMICS LLC·Filed 2002·Granted Mar 27, 2007·66 cites·11 claims
- 0395US7270835B2Compositions that treat or inhibit pathological conditions associated with inflammatory responseMETAPROTEOMICS LLC·Filed 2003·Granted Sep 18, 2007·61 cites·8 claims
- 0493US7790205B2Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseMETAPROTEOMICS LLC·Filed 2006·Granted Sep 7, 2010·23 cites·18 claims
- 0591US7279185B2Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2METAPROTEONICS LLC·Filed 2004·Granted Oct 9, 2007·40 cites·3 claims
- 0690US7722903B2Modulation of inflammation by hops fractions and derivativesMETAPROTEOMICS LLC·Filed 2006·Granted May 25, 2010·5 cites·4 claims
- 0788US7820206B2Modulation of inflammation by hops fractions and derivativesMETAPROTEOMICS LLC·Filed 2006·Granted Oct 26, 2010·3 cites·8 claims
- 0888US7666449B2Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicityMETAPROTEOMICS LLC·Filed 2006·Granted Feb 23, 2010·4 cites·8 claims
- 0987US7815944B2Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicityMETAPROTEOMICS LLC·Filed 2006·Granted Oct 19, 2010·3 cites·12 claims
- 1087US7807203B2Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicityMETAPROTEOMICS LLC·Filed 2009·Granted Oct 5, 2010·3 cites·5 claims
- 1184US7682636B2Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2METAPROTEOMICS LLC·Filed 2007·Granted Mar 23, 2010·5 cites·6 claims
- 1283US8142819B2Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseTRIPP MATTHEW L·Filed 2003·Granted Mar 27, 2012·14 cites·12 claims
- 1382US7794757B2Modulation of inflammation by hops fractions and derivativesMETAPROTEOMICS LLC·Filed 2006·Granted Sep 14, 2010·3 cites·4 claims
- 1482US6979470B2Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2METAPROTEOMICS LLC·Filed 2002·Granted Dec 27, 2005·14 cites·16 claims
- 1580US8557306B2Compositions that treat or inhibit pathological conditions associated with inflammatory responseTRIPP MATTHEW L·Filed 2012·Granted Oct 15, 2013·4 cites·9 claims
- 1680US7919125B2Modulation of inflammation by hops fractions and derivativesMETAPROTEOMICS LLC·Filed 2010·Granted Apr 5, 2011·3 cites·4 claims
- 1780US6908630B2Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2METAPROTEOMICS LLC·Filed 2001·Granted Jun 21, 2005·10 cites·25 claims
- 1879US6629835B2Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2METAPROTEOMICS LLC·Filed 2001·Granted Oct 7, 2003·8 cites·6 claims
- 1976US8257754B2Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory responseTRIPP MATTHEW L·Filed 2012·Granted Sep 4, 2012·2 cites·19 claims
- 2070US7811610B2Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicityMETAPROTEOMICS LLC·Filed 2004·Granted Oct 12, 2010·4 cites·7 claims
- 2168US8168234B2Compositions that treat or inhibit pathological conditions associated with inflammatory responseTRIPP MATTHEW L·Filed 2007·Granted May 1, 2012·0 cites·6 claims
- 2263US2004115290A1Modulation of inflammation by hops fractions and derivativesFiled 2003·Application pending·0 cites
- 2354US2004219240A1Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicityFiled 2004·Application pending·0 cites
- 2451US2009263522A1Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2BABISH JOHN G·Filed 2005·Application pending·0 cites
- 2548US2004247700A1Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2Filed 2002·Application pending·0 cites
- 2648US2003206972A1Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effectFiled 2001·Application pending·0 cites
- 2746US8486457B2Compositions that treat or inhibit pathological conditions associated with inflammatory responseTRIPP MATTHEW L·Filed 2003·Granted Jul 16, 2013·0 cites·12 claims
- 2842US2002120001A1Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effectASHNI NATURACEUTICALS INC·Filed 2001·Application pending·0 cites
- 2942US2003096027A1Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2Filed 2002·Application pending·0 cites
- 3041US2002076452A1Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2ASHNI NATURACEUTICALS INC·Filed 2001·Application pending·0 cites
- 3141US2002110604A1Composition exhibiting synergistic antioxidant activityASHNI NATURACEUTICALS INC·Filed 2001·Application pending·0 cites
- 3241US2002077350A1Compositions exhibiting synergistic inhibition of the expression and/or activity of clyclooxygenase-2ASHNI NATURACEUTICALS INC·Filed 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →